Health & WellnessTech
People of Color
Corvidane
Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH.
New York,
NY
Investment type:
Equity
(SAFE)
Target raise:
$50,000
- $1,000,000
Minimum investment:
$100
$100
End date:
May 01, 2022
May 01, 2022
ended
Share
Highlights
- CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
- Awarded $700k from Dutch government to perform more studies on our drug Corvida’s potential.
- Results of Corvida’s affect on genes associated with atherosclerosis due in 2022.
- Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
Our Story
Corvidane is developing a new approach to treat heart and liver diseases
Our Ambition
In 5 years, we anticipate we will be selling and/or or licensing our drug Corvida.